Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 13/20 | 0.48 |
| ▸ | OXTR | P30559 | 3/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005662 | 1.00 | CCKBR (0.48) | CCKBROXTRPSEN1PSEN2APH1B | |
| SCHEMBL6005682 | 0.93 | CCKBR (0.55) | CCKBROXTRPSEN1PSEN2APH1B | |
| SCHEMBL6003867 | 0.89 | CCKBR (0.55) | CCKBROXTRPSEN1PSEN2APH1B | |
| SCHEMBL6006022 | 0.89 | CCKBR (0.45) | CCKBROXTRPSEN1PSEN2APH1B | |
| SCHEMBL6005806 | 0.89 | CCKBR (0.45) | CCKBROXTRPSEN1PSEN2APH1B | |
| SCHEMBL6006715 | 0.84 | CCKBR (0.68) | CCKBROXTRKCNH2 | |
| SCHEMBL6005228 | 0.84 | CCKBR (0.68) | CCKBROXTRKCNH2 | |
| SCHEMBL6006725 | 0.84 | CCKBR (0.68) | CCKBROXTRKCNH2 | |
| SCHEMBL6005685 | 0.83 | CCKBR (0.56) | CCKBRPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6005992 | 0.81 | CCKBR (0.62) | CCKBROXTRKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105509-B2 | Benzodiazepine derivatives as APP modulators | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-12 | — | — | US | disclosed |
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | MERCK SHARPE & DOHME LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1294702-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LTD. (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2001090084-A1 | BENZODIAZEPINE DERIVATIVES AS APP MODULATORS | MERCK SHARP & DOHME LIMITED (GB) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082572-A1 | Benzodiazepine derivatives as app modulators | BACE1, PSEN1, APP | CCKBR 642/4885OXTR 773/4885PSEN1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.